Your Insurance Approved Your Drug — Here's Why You Still Can't Afford It

You did everything right. Your doctor submitted the prior authorization. You waited. You got the letter: approved. And then the pharmacy called with the cost.

The approval you spent weeks waiting for does not mean the drug is affordable. For specialty medications — biologics, infusion therapies, gene therapies, and many other high-cost drugs — insurance approval and financial access are two entirely separate problems. Understanding the difference between them is the first step toward closing the gap.

Why Approval Doesn't Mean Affordable

The insurance approval process determines whether your plan will cover a drug at all. It does not determine how much you will pay. That calculation happens separately, through a set of cost-sharing rules built into your plan's benefit design — rules most people don't read until the pharmacy hands them a bill they weren't expecting.

Specialty drugs can carry list prices of $10,000 to $100,000 per year or more, depending on the medication and condition. According to the Kaiser Family Foundation, out-of-pocket costs for specialty drugs remain a significant barrier for patients even after coverage approval, particularly as more plans shift specialty medications to high cost-sharing tiers.

Approval is the gate. The cost-sharing structure is what lives on the other side of it.

The Coinsurance Problem

Most insurance plans don't charge a flat copay for specialty drugs. They charge coinsurance — a percentage of the drug's cost, which you pay after your deductible is met.

If your plan has 20% coinsurance and your drug costs $8,000 per month, your share is $1,600 — every month. For a drug at $15,000 per month, 20% coinsurance means $3,000 out of pocket, every single month, with insurance.

Coinsurance structures like this are standard on specialty tiers. The plan is covering the other 80%. That is technically insurance doing what insurance is supposed to do. It still leaves most patients unable to fill the prescription.

Specialty Tiers and How Plans Classify Your Drug

Commercial insurance plans organize covered medications into tiers, each with different cost-sharing requirements. Generic drugs typically occupy Tiers 1 and 2, with low or no cost sharing. Brand-name drugs land in Tier 3. Specialty drugs — biologics, infusion therapies, oncology drugs, immunoglobulins — are usually placed in Tier 4 or Tier 5.

Tier 4 and Tier 5 typically carry the highest cost-sharing the plan offers, usually in the form of coinsurance rather than a flat copay. The Centers for Medicare and Medicaid Services recognizes the specialty tier as a distinct category in Medicare Part D plans, where it is defined by a list price threshold and carries specific coverage requirements. Commercial plans have adopted similar structures.

The tier your drug is assigned to is not random, and it is not fixed. Plans adjust formularies annually, and drugs can move between tiers at renewal — sometimes without notice.

The Deductible: Before Any Cost Sharing Applies

Before coinsurance even becomes the calculation, many patients must first meet their deductible — the amount you pay in full before your insurance begins sharing costs at all.

Deductibles for employer-sponsored plans and ACA marketplace plans commonly run from $1,500 to $8,000 per year, according to KFF data on employer health benefits. For a specialty drug that costs thousands of dollars per month, you may be paying full price for the first one or two fills of every plan year.

This means that the coinsurance figure your plan quotes you is actually your best-case scenario. Before you hit your deductible, the number is higher.

The Out-of-Pocket Maximum: Real, but Not Immediate

Every ACA-compliant insurance plan is required to cap your out-of-pocket spending each year. In 2025, the federal out-of-pocket maximum for an individual is $9,450 for marketplace plans, with employer-sponsored plans often setting their own limits within regulatory bounds.

The out-of-pocket maximum is the point at which your plan covers 100% of covered costs for the rest of the plan year. For patients on high-cost specialty drugs, reaching that limit can be a financial lifeline.

The challenge is getting there. If your drug costs $1,600 per month in coinsurance, you will spend approximately $9,600 before you hit a typical out-of-pocket maximum — which means five to six months of full cost-sharing before the relief arrives. Most patients cannot absorb that gap.

Some specialty drugs come with free drug programs or manufacturer assistance specifically designed to bridge this wait. Others do not.

What Actually Helps

Several assistance options exist, and they operate differently depending on your insurance type and income level.

Manufacturer copay cards and patient assistance programs. For patients with commercial insurance, most major specialty drug manufacturers offer copay cards that can reduce your out-of-pocket cost to zero or near zero per fill. These programs are applied at the pharmacy counter and can be accessed through the manufacturer's patient support hub or your specialty pharmacy.

There is a significant limitation: copay cards do not work on government-funded insurance. Medicare, Medicaid, and TRICARE beneficiaries are ineligible for manufacturer copay assistance under federal anti-kickback rules. Using a copay card while on federal insurance can constitute fraud.

Copay accumulators. Many commercial plans now use copay accumulator or copay maximizer programs, which intercept copay card payments and prevent them from counting toward your deductible and out-of-pocket maximum. This means you may use a manufacturer card for several months and then face full out-of-pocket costs once the card balance is exhausted — with no progress toward your deductible. If you use a copay card, ask your specialty pharmacist whether your plan uses an accumulator.

Independent patient assistance foundations. Several nonprofit foundations offer financial assistance for specific drug categories or disease areas, regardless of insurance type. The Patient Advocate Foundation (PAN Foundation), HealthWell Foundation, Good Days, and NeedyMeds maintain funds that cover copays, coinsurance, and sometimes premiums. These funds open and close throughout the year based on available resources; eligibility requirements and fund availability vary by program.

Hospital and health system financial assistance programs. If your drug is administered in a hospital or health system outpatient setting, the facility itself may have a financial assistance program. These programs, sometimes called charity care, are required at nonprofit hospitals and can apply to drug and infusion costs in addition to hospital services.

Patient assistance programs for uninsured or low-income patients. Most major manufacturers maintain separate programs for patients who are uninsured or whose income falls below a certain threshold. These programs typically provide the drug at no cost and are distinct from the commercial copay card programs. Income documentation is generally required.

Appealing Your Cost-Sharing Tier

One option most patients don't know exists: you can appeal to have your drug moved to a lower cost-sharing tier.

A tier exception request asks your insurance plan to apply lower cost-sharing requirements to a drug, typically on the basis that no other drug in the lower tier is clinically appropriate for your condition. Tier exception rights are required for Medicare Part D plans under CMS rules, and many state insurance regulations extend similar protections to commercial plans.

Your prescribing physician will need to submit the exception request and document why the alternatives at lower tiers are not medically appropriate for you. The plan is required to respond within a defined timeframe. If the request is denied, you have the right to appeal.

This process takes time, and it requires your doctor's participation. It is worth pursuing if the cost difference between tiers is significant and the alternatives are genuinely inappropriate for your care.

A Word on Annual Resets

Cost-sharing structures reset at the start of every plan year. This means that if you spent the first half of the year reaching your out-of-pocket maximum, you will begin again at zero on January 1. For patients on ongoing specialty therapies, the cycle of meeting deductibles and out-of-pocket maximums before coverage kicks in fully is an annual event.

Switching from a calendar-year deductible to a plan with a different benefit year, or timing plan enrollment strategically, can sometimes reduce the financial impact of that reset. A benefits navigator or patient assistance coordinator through your specialty pharmacy can help you think through the options available during open enrollment.

The System Is Working as Designed

This is not a billing error. Cost-sharing structures on specialty drugs are intentional plan design, calibrated to shift high-cost drug spending toward the patient. According to a 2023 KFF analysis of commercial plan benefit design, specialty tier cost sharing has increased consistently as specialty drug spending has grown.

Knowing how it works does not make the bill smaller. But it does tell you what lever to pull — whether that is a copay card, a foundation grant, a tier exception, or a conversation with your pharmacy about assistance programs you haven't tried yet. The approval letter is one piece. The assistance landscape is another. Both require navigation.

Sources: Kaiser Family Foundation, "Cost Sharing for Employer-Sponsored Coverage," 2023; KFF, "Out-of-Pocket Limits for Marketplace Plans," 2025; CMS, Medicare Prescription Drug Benefit Manual, Chapter 6 (Part D Cost Sharing); CMS, Medicare Part D Special Enrollment and Formulary Exceptions regulations; Patient Advocate Foundation; HealthWell Foundation; Good Days.